Setmelanotide Case Report Published in Nephron on Sept. 15, 2026

A new publication involving setmelanotide appeared in the journal Nephron on September 15, 2026. The paper is titled "Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review." It is described as a real-world case report combined with a literature review. The publication addresses the use of liraglutide followed by setmelanotide therapy in patients with Bardet-Biedl Syndrome. According to the listing, the work examines metabolic and renal outcomes in this context. No specific findings, results, or conclusions from the publication were provided beyond its title and format. This entry reflects only that the publication exists and its stated scope, not any outcome data. Readers interested in the details of the metabolic and renal outcomes discussed should consult the full text via the source link. Setmelanotide remains an approved therapy, and this publication represents a new addition to the literature on its use in Bardet-Biedl Syndrome. For general background on this compound, readers can consult the compound overview available alongside this brief.